Recursion Pharmaceuticals (NASDAQ:RXRX) Coverage Initiated by Analysts at Morgan Stanley

Morgan Stanley initiated coverage on shares of Recursion Pharmaceuticals (NASDAQ:RXRX - Free Report) in a research note published on Thursday morning, Marketbeat Ratings reports. The brokerage issued an equal weight rating and a $5.00 price objective on the stock.

Separately, Needham & Company LLC reduced their price target on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $7.00.

Recursion Pharmaceuticals Price Performance

NASDAQ:RXRX traded up $0.05 during trading hours on Thursday, reaching $5.26. 16,582,108 shares of the company traded hands, compared to its average volume of 15,972,568. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.11 and a quick ratio of 4.11. The firm's 50-day moving average is $4.85 and its 200-day moving average is $6.12. The stock has a market cap of $2.14 billion, a P/E ratio of -2.97 and a beta of 0.91. Recursion Pharmaceuticals has a 1-year low of $3.79 and a 1-year high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The company had revenue of $14.75 million for the quarter, compared to analysts' expectations of $18.12 million. During the same quarter in the prior year, the business posted ($0.39) EPS. The company's revenue for the quarter was up 7.2% compared to the same quarter last year. Equities research analysts expect that Recursion Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. ARK Investment Management LLC raised its stake in shares of Recursion Pharmaceuticals by 7.6% in the 1st quarter. ARK Investment Management LLC now owns 34,815,502 shares of the company's stock valued at $184,174,000 after acquiring an additional 2,469,104 shares during the period. Vanguard Group Inc. grew its stake in Recursion Pharmaceuticals by 40.1% during the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock valued at $229,908,000 after purchasing an additional 9,737,196 shares in the last quarter. Softbank Group CORP. bought a new stake in shares of Recursion Pharmaceuticals in the fourth quarter worth $99,152,000. Kinnevik AB publ raised its stake in shares of Recursion Pharmaceuticals by 12.8% in the 1st quarter. Kinnevik AB publ now owns 13,434,171 shares of the company's stock valued at $71,067,000 after purchasing an additional 1,528,503 shares in the last quarter. Finally, Novo Holdings A S bought a new position in Recursion Pharmaceuticals during the 4th quarter worth approximately $68,375,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.